Company news
Alphamab Oncology news in 2021
Alphamab Oncology's news releases, calls and decks from 2021, newest first.
Voluntary announcement - abstracts and e-posters of research updates on KN046 and KN026 for presentation at 2021 asco annual meeting
May 6, 2021
Alphamab Oncology: (1) Proposed granting of general mandates to repurchase shares and to issue new shares; (2) proposed re-election of the retiring directors; (3) proposed re-appointment of auditors; and (4) notice of annual general meeting
April 27, 2021
Voluntary announcement - preliminary safety tolerability and efficacy results of KN046 in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer released for e-poster presentation at 2021 aacr annual meeting
April 12, 2021
Voluntary announcement - appointment of chief medical officer and chief financial officer
March 30, 2021
Alphamab Oncology Reports Full Year 2020 Financial Results and Business Highlights
March 23, 2021
Alphamab Oncology: Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.
March 9, 2021
Voluntary announcement - ind approval received for a phase ii clinical trial of KN046 in the U.S.
March 8, 2021